In 2024, the new price of dabrafenib will be disclosed

Dabrafenib is an orally administered targeted therapy drug that is a BRAF kinase inhibitor. Its main role is to target cancers such as malignant melanoma (melanoma) and non-small cell lung cancer that carry the BRAF V600 mutation. BRAF is a gene that plays an important role in cell signaling, and BRAF V600 mutation is one of the common mutations that can lead to abnormal proliferation and growth of cancer cells.

Dabrafenib is now on the market in China and has been included in medical insurance. Patients can purchase it directly in China. However, its price is relatively high, about more than 10,000 yuan. It is recommended to consult the local hospital or pharmacy for specific costs. In comparison, the price of foreign generic drugs of dabrafenib is more affordable, especially the price of generic drugs produced in Laos, which is only about two to three thousand yuan, which is far lower than the domestic price. It should be emphasized that these foreign generic drugs are highly similar to domestic original drugs in terms of drug ingredients. Therefore, patients can flexibly choose a suitable drug source based on their own economic status and actual needs.

The working mechanism of dabrafenib is to block downstream signaling pathways by inhibiting the activity ofBRAFkinase, thereby inhibiting the proliferation and survival of cancer cells. It blocks the signaling pathway in cancer cells such as malignant melanoma and non-small cell lung cancer by binding to the activation site of BRAF protein and preventing its phosphorylation activity.

As a targeted therapy, dabrafenib is often used to treat cancer that has spread to other sites or cannot be removed with surgery. Compared with traditional chemotherapy drugs, dabrafenib is more selective, targeting tumor cells more precisely, causing less damage to healthy cells, and generally causing fewer side effects.

However, dabrafenib is not suitable for all types of cancer. It mainly targets tumors carrying specific genetic mutations. Therefore, before using dabrafenib, genetic testing is often required to determine whether a patient's tumor is suitable for this treatment.